In line with this, the immunophenotypic profiling of circulating immune cells revealed that treated pts experienced a decrease in myeloid cell subtypes over time (i.e. e-MDSCs, M-MDSCs and PDL1 + non-classical monocytes); and a simultaneous increase in CD8 + TEM lymphocytes, a key player in the anti-tumor response especially when generated at high frequencies. Here, CD8A is linked to neoplasm.